Alerts will be sent to your verified email
Verify Email
SYNGENE
|
Syngene Internation.
|
Laurus Labs
|
Sun Pharma Adv. Res
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
12.33 % | 18.77 % | -64.48 % |
|
5yr Avg Net Profit Margin
|
15.3 % | 11.95 % | -361.01 % |
|
Price to Book
|
5.41 | 10.38 | 0.0 |
|
P/E
|
50.45 | 91.26 | 0.0 |
|
5yr Avg Cash Conversion Cycle
|
-6453.7 Days | 91.73 Days | 80.33 Days |
|
5yr Average Interest Coverage Ratio
|
16.15 | 8.98 | -97.45 |
|
5yr Avg ROCE
|
13.11 % | 22.73 % | 208.61 % |
|
5yr Avg Operating Profit Margin
|
29.04 % | 24.36 % | -357.39 % |
|
5 yr average Debt to Equity
|
0.15 | 0.56 | -0.27 |
|
5yr CAGR Net Profit
|
4.15 % | -18.29 % | 9.0 % |
|
5yr Average Return on Assets
|
7.88 % | 8.99 % | -68.32 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
52.68 % | 27.59 % | 65.67 % |
|
Share Pledged by Promoters
|
0.0 | 2.69 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-17.61 % | 0.32 % | -3.42 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
17.91 % | 3.01 % | 0.7 % |
|
Syngene Internation.
|
Laurus Labs
|
Sun Pharma Adv. Res
|
|---|